Hospital
Prisma Health-Midlands
Prisma Health-Midlands was paid $6.88M by Medicaid between Jan 2018 and Dec 2024, across 184 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoPRISMA HEALTH-MIDLANDS
COLUMBIA, SC 29201
COLUMBIA, SC 29201
33aNPI1134333206assigned 05/09/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.88M
24GClaims330,453
24DCodes billed184
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#46 of 115
Median peer was paid$2.47M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MILLER, POLLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,078 | $1.12M | |
| 2019 | 53,031 | $1.14M | |
| 2020 | 34,200 | $714K | |
| 2021 | 42,001 | $930K | |
| 2022 | 52,888 | $1.13M | |
| 2023 | 48,964 | $1.00M | |
| 2024incomplete | 46,291 | $833K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 17,346 | 14,292 | $964K |
| 80053 | Comprehensive metabolic panel | 7.7% | 10,897 | 8,842 | $528K |
| 80048 | Basic metabolic panel (calcium, ionized) | 7.2% | 11,291 | 8,888 | $494K |
| 94010 | 6.0% | 1,754 | 1,697 | $414K | |
| 36415 | Collection of venous blood by venipuncture | 5.4% | 7,880 | 4,443 | $374K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.0% | 7,447 | 4,255 | $346K |
| 81001 | 4.6% | 13,028 | 11,371 | $315K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 3,238 | 2,698 | $312K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.2% | 14,780 | 12,588 | $292K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.3% | 6,496 | 4,958 | $226K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 7,149 | 6,166 | $189K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 7,669 | 6,662 | $178K |
172 more codes
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.5% | 192 | $173K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.3% | 2,427 | $155K |
| 81025 | 2.1% | 7,387 | $147K | |
| 84702 | 1.8% | 2,527 | $122K | |
| 86900 | 1.6% | 1,607 | $113K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,048 | $103K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 3,044 | $81K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 2,608 | $73K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 2,320 | $72K |
| 87210 | <1% | 845 | $67K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 176 | $60K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,046 | $52K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 337 | $52K |
| 71250 | <1% | 343 | $50K | |
| 76642 | <1% | 1,061 | $48K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,644 | $43K |
| 85027 | <1% | 4,668 | $43K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,956 | $42K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 735 | $39K |
| 86850 | <1% | 823 | $38K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,257 | $36K |
| 76830 | Ultrasound, transvaginal | <1% | 356 | $35K |
| 82565 | <1% | 138 | $33K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,854 | $31K |
| 86901 | <1% | 1,732 | $30K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,326 | $27K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 866 | $26K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 344 | $25K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,793 | $25K |
| A4649 | Surgical supply; miscellaneous | <1% | 202 | $23K |
| 87077 | <1% | 994 | $21K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 238 | $20K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 320 | $20K |
| 77066 | Tomosynthesis, mammo | <1% | 259 | $19K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 474 | $19K |
| 76801 | <1% | 1,185 | $15K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 593 | $15K |
| 73560 | <1% | 453 | $14K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,185 | $12K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,823 | $11K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 179 | $10K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,915 | $10K |
| G0378 | Hospital observation service, per hour | <1% | 3,236 | $10K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 994 | $10K |
| 87081 | <1% | 79 | $9K | |
| 84112 | <1% | 42 | $8K | |
| 94060 | <1% | 28 | $7K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,145 | $7K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,095 | $7K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 15 | $7K |
| J3490 | Unclassified drugs | <1% | 6,237 | $7K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 801 | $6K |
| 73630 | <1% | 104 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,658 | $6K |
| 76937 | <1% | 784 | $6K | |
| 81003 | <1% | 438 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,369 | $5K |
| 94761 | <1% | 249 | $5K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 414 | $5K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,826 | $4K |
| 84484 | <1% | 5,219 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 684 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 150 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 133 | $3K |
| J1815 | Injection, insulin, per 5 units | <1% | 769 | $3K |
| 73030 | <1% | 80 | $3K | |
| 73502 | <1% | 58 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 84 | $2K |
| 85610 | <1% | 2,049 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,788 | $2K |
| 93971 | <1% | 52 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 254 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 847 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,330 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,259 | $2K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 18 | $1K |
| 76641 | <1% | 17 | $1K | |
| C1769 | Guide wire | <1% | 182 | $1K |
| 83735 | <1% | 6,462 | $1K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 996 | $1K |
| 72100 | <1% | 95 | $1K | |
| 94664 | <1% | 63 | $1K | |
| 84703 | <1% | 159 | $1K | |
| 76770 | <1% | 15 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 139 | $980.77 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15 | $958.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,099 | $856.78 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,375 | $849.57 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,538 | $838.72 |
| 85379 | <1% | 451 | $777.36 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 942 | $669.80 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 953 | $667.58 |
| 80076 | <1% | 173 | $602.59 | |
| 82570 | <1% | 132 | $430.15 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 13 | $360.51 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 15 | $353.74 |
| 73130 | <1% | 26 | $335.34 | |
| A9270 | Non-covered item or service | <1% | 4,578 | $292.50 |
| 82550 | <1% | 879 | $212.54 | |
| 85018 | <1% | 31 | $199.68 | |
| 82077 | <1% | 48 | $117.61 | |
| 80069 | <1% | 33 | $66.68 | |
| 88304 | <1% | 68 | $61.69 | |
| J2704 | Injection, propofol, 10 mg | <1% | 543 | $23.35 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 388 | $10.68 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,290 | $2.28 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 110 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,669 | $0.00 |
| 82553 | 0% | 546 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 74 | $0.00 |
| 96376 | 0% | 2,084 | $0.00 | |
| 83690 | 0% | 4,602 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 621 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 139 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 30 | $0.00 |
| 86140 | 0% | 72 | $0.00 | |
| 36410 | 0% | 259 | $0.00 | |
| 85730 | 0% | 1,607 | $0.00 | |
| 83880 | 0% | 1,189 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 275 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 1,003 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 4,393 | $0.00 |
| 83605 | 0% | 1,148 | $0.00 | |
| 88342 | 0% | 277 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 480 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 563 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 283 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 415 | $0.00 |
| 88307 | 0% | 83 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 52 | $0.00 |
| 83615 | 0% | 85 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 19 | $0.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 111 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 29 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 117 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 40 | $0.00 |
| 87040 | 0% | 84 | $0.00 | |
| 86803 | 0% | 64 | $0.00 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 17 | $0.00 |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 50 | $0.00 |
| 94729 | 0% | 147 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 523 | $0.00 |
| 84550 | 0% | 134 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 1,278 | $0.00 |
| 94726 | 0% | 98 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,098 | $0.00 |
| 93976 | 0% | 967 | $0.00 | |
| 87186 | 0% | 696 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 190 | $0.00 |
| 84145 | 0% | 128 | $0.00 | |
| 84156 | 0% | 132 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 135 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 3,440 | $0.00 |
| 84100 | 0% | 492 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 226 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 162 | $0.00 |
| 99152 | 0% | 31 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 177 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 81 | $0.00 |
| 97161 | 0% | 62 | $0.00 | |
| 90715 | 0% | 13 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 69 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 55 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 15 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 34 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 78 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 26 | $0.00 |
| 85014 | 0% | 21 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 32 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, POLLY (VP PAYOR STRATEGIES ALIGNMENT)
Parent organizationPRISMA HEALTH-MIDLANDS
| Provider | Location | Paid |
|---|---|---|
| Prisma Health-Midlands | Columbia, SC | $74.58M |
| Prisma Health-Midlands | Columbia, SC | $68.26M |
| Prisma Health-Upstate | Greenville, SC | $25.04M |
| Prisma Health-Upstate | Greenville, SC | $21.98M |
| Prisma Health-Upstate | Greenville, SC | $19.69M |
| Prisma Health-Upstate | Seneca, SC | $15.64M |
| Prisma Health-Midlands | Columbia, SC | $11.77M |
| Prisma Health-Upstate | Greenville, SC | $10.74M |
| Greenville Health Corporation | Greenville, SC | $8.90M |
| Prisma Health-Upstate | Greenville, SC | $8.32M |
| Prisma Health-Upstate | Greenville, SC | $7.45M |
| Prisma Health University Medical Group | Greenville, SC | $7.44M |
| Prisma Health-Midlands | Coulmbia, SC | $7.43M |
| Prisma Health Tuomey | Sumter, SC | $6.84M |
| Prisma Health-Midlands | Columbia, SC | $6.77M |
| Prisma Health-Upstate | Greenville, SC | $6.37M |
| Prisma Health-Upstate | Greenville, SC | $5.00M |
| Prisma Health-Upstate | Greenville, SC | $4.65M |
| Prisma Health-Midlands | Columbia, SC | $4.63M |
| Prisma Health-Upstate | Seneca, SC | $4.48M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.